• Corpus ID: 22532892

Pharmaceutical development of a parenteral lyophilized formulation of the novel antitumor agent aplidine.

@article{Nuijen2000PharmaceuticalDO,
  title={Pharmaceutical development of a parenteral lyophilized formulation of the novel antitumor agent aplidine.},
  author={Bastiaan Nuijen and Marjan Bouma and Roland E. C. Henrar and Pablo Floriano and Jos{\'e} Jimeno and Herre Talsma and Jantien J. Kettenes-van den Bosch and Albert J. R. Heck and Auke Bult and Jos H. Beijnen},
  journal={PDA journal of pharmaceutical science and technology},
  year={2000},
  volume={54 3},
  pages={
          193-208
        },
  url={https://api.semanticscholar.org/CorpusID:22532892}
}
The prototype, containing 500 micrograms aplidine and 25 mg D-mannitol per vial, was found to be the optimal formulation in terms of solubility, length of lyophilization cycle, and dosage requirements in the forthcoming Phase I clinical studies.
View on PubMed
28 Citations
Highly Influential Citations
1
Background Citations
4
Methods Citations
2

28 Citations

Development of a Lyophilized Parenteral Pharmaceutical Formulation of the Investigational Polypeptide Marine Anticancer Agent Kahalalide F

It was found that a combination of polysorbate 80 and citric acid monohydrate is necessary to solubilize kahalalide F and lyophilized products containing sucrose as a bulking agent were more stable compared to the products containing mannitol.

Pharmaceutical development of a lyophilised dosage form for the investigational anticancer agent Imexon using dimethyl sulfoxide as solubilising and stabilising agent.

DMSO is shown to provide the stability required for Imexon during manufacturing and to be a suitable vehicle for lyophilisation, which was employed to gain sufficient shelf-life for the final product.

Pharmaceutical development of the novel metal-based anticancer agents NAMI-A and AP 5280

The pharmaceutical development of the two novel metal-based anticancer agents NAMI-A and AP 5280 is described in this thesis, starting with the development of analytical methods for the quality…

Formulation, development and evaluation of injectable formulation of Aspirin

The study opens the chances of preparing lyophilized formulation of poorly-water soluble drugs by developing and manufacture a stable parenteral formulation for Aspirin, a non steroidal anti-inflammatory agent.

Plitidepsin: design, development, and potential place in therapy

This review critically analyzes the published studies on plitidepsin in hematological malignancies and solid tumors and discusses its current role and future perspectives in treating thesemalignancies.

Plitidepsin: design, development, and potential place in therapy

This review critically analyzing the published studies on plitidepsin in hematological malignancies and solid tumors discusses its current role and future perspectives in treating these malignancies and its design, pharmaceutical data, and mechanism of action.

HPLC-UV METHOD DEVELOPMENT AND IMPURITY PROFILING OF THE MARINE ANTICANCER AGENT APLIDINE IN RAW DRUG SUBSTANCE AND PHARMACEUTICAL DOSAGE FORM

The development and validation of a reversed-phase high performance liquid chromatographic (RP-HPLC) method with ultra-violet (UV) detection for the quantification and purity determination of…

A Novel One-Step Drug-Loading Procedure for Water-Soluble Amphiphilic Nanocarriers

A straightforward, economical, and innovative drug-loading procedure that consists in dissolving both the drug and an amphiphilic diblock copolymer in a water/tert-butanol mixture that is subsequently freeze-dried and it is demonstrated that monodisperse 20-60 nm-sized drug-loaded polymeric micelles are produced directly and spontaneously upon rehydration of the freeze-Dried cake.

Pharmaceutical quality control of the investigational polymer-conjugated platinum anticancer agent AP 5280.

The combined results of the analyses performed on AP 5280 drug substance provided a meaningful picture of its structure, size, and integrity--an excellent basis for its quality control.

Development of a bladder instillation of the indoloquinone anticancer agent EO-9 using tert-butyl alcohol as lyophilization vehicle

It is revealed that tert-butyl alcohol (TBA) can be used to both dramatically improve the solubility and stability of EO-9 and to shorten the freeze-drying cycle by increasing the sublimation rate.